Savara (SVRA) Long-Term Debt Repayments (2017 - 2025)

Savara's (SVRA) quarterly Long-Term Debt Repayments came in at -$1000.0 in Q3 2025, down 100.0% on a QoQ basis from $27.2 million in Q1 2025.

Savara (SVRA) Long-Term Debt Repayments (2017 - 2025) Analysis & Trends

Savara (SVRA) has 2 years of Long-Term Debt Repayments data on file, last reported at -$1000.0 in Q3 2025.

On a quarterly basis, Long-Term Debt Repayments changed N/A year-over-year to -$1000.0 in Q3 2025; TTM through Dec 2025 was $27.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $27.2 million, changed N/A from the prior year.
Long-Term Debt Repayments for Q3 2025 stood at -$1000.0, down from $27.2 million in the prior quarter.
Over the last five years, Long-Term Debt Repayments for SVRA reached as high as $27.2 million in Q1 2025 and fell as low as -$1000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Repayments (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	7.64 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Savara	1.24 Bn	1.24 Bn	-	-

Download Data